Kim Glisson is currently the Executive Director of Sales and Marketing for the Rare Disease Business Unit at Amgen, where they lead initiatives for products such as ACTIMMUNE, KRYSTEXXA, and TEPEZZA. Previously, Kim held leadership roles at companies such as Lundbeck and UCB, where they specialized in marketing and commercialization strategies. They have a Bachelor of Science in Biomedical Sciences from Western Michigan University and an MBA from the University of Maryland University College. Kim's career reflects a strong focus on brand leadership in the pharmaceutical industry, marked by impactful contributions to early-stage commercialization and marketing.
This person is not in the org chart
This person is not in any teams
This person is not in any offices